EyePoint Pharmaceuticals, Inc. (EYPT) has reported a completed transaction involving Executive Vice Chair Nancy Lurker. On July 10, 2024, Lurker acquired 11,111 shares of EyePoint Pharmaceuticals' common stock at no cost, as part of an exercise or conversion of a derivative security. Following this transaction, Lurker directly holds a total of 94,462 shares. Additionally, there is an indirect holding of 126,889 shares by a family trust associated with Lurker. The transaction reflects a strengthening of Lurker's investment in the company and may be of interest to current and potential investors.

EyePoint Pharmaceuticals, Inc. (EYPT) has reported a completed transaction involving Executive Vice Chair Nancy Lurker. On July 10, 2024, Lurker acquired 11,111 shares of EyePoint Pharmaceuticals' common stock at no cost, as part of an exercise or conversion of a derivative security. Following this transaction, Lurker directly holds a total of 94,462 shares. Additionally, there is an indirect holding of 126,889 shares by a family trust associated with Lurker. The transaction reflects a strengthening of Lurker's investment in the company and may be of interest to current and potential investors.